Seattle Genetics to Present at Credit Suisse Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Seattle Genetics (SGEN) Recorded Record Sales Following Label Expansion; Needham & Company Reiterates Buy
October 30, 2015 1:12 PM EDTNeedham & Company reiterated a Buy rating and $60.00 price target on Seattle Genetics (NASDAQ: SGEN) fallowing the company's 3Q earnings results. Adcetris reported record quarterly sales of $59 million, following the company's label expansion into post transplant Hodgkin's lymphoma (HL).
Analyst Chad Messer commented, "Following... More
